Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Gains from Investment Securities (2016 - 2025)

Protalix BioTherapeutics has reported Gains from Investment Securities over the past 16 years, most recently at $1.2 million for Q4 2025.

  • Quarterly results put Gains from Investment Securities at $1.2 million for Q4 2025, up 204.71% from a year ago — trailing twelve months through Dec 2025 was $1.6 million (up 304.94% YoY), and the annual figure for FY2025 was $2.1 million, down 71.73%.
  • Gains from Investment Securities for Q4 2025 was $1.2 million at Protalix BioTherapeutics, down from $1.4 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for PLX hit a ceiling of $1.5 million in Q4 2023 and a floor of -$526000.0 in Q3 2022.
  • Median Gains from Investment Securities over the past 5 years was $31500.0 (2021), compared with a mean of $282499.5.
  • Biggest five-year swings in Gains from Investment Securities: plummeted 1853.33% in 2022 and later surged 11246.08% in 2025.
  • Protalix BioTherapeutics' Gains from Investment Securities stood at $228000.0 in 2021, then soared by 435.53% to $1.2 million in 2022, then increased by 24.24% to $1.5 million in 2023, then crashed by 74.82% to $382000.0 in 2024, then skyrocketed by 204.71% to $1.2 million in 2025.
  • The last three reported values for Gains from Investment Securities were $1.2 million (Q4 2025), $1.4 million (Q3 2025), and -$20000.0 (Q2 2025) per Business Quant data.